DDInter1653 DDInter1376
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Selegiline {u} (Compound) resembles {v} (Compound) Phenelzine
Selegiline {u} (Compound) resembles {v} (Compound) Benzyl alcohol
Selegiline {u} (Compound) binds {v} (Gene) MAOA
Selegiline {u} (Compound) palliates {v} (Disease) Alzheimer's disease
Selegiline {u} (Compound) is included by {v} (Pharmacologic Class) Monoamine Oxidase-B Inhibitors
Selegiline {u} (Compound) causes {v} (Side Effect) Thrombocytopenia
Selegiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Prasugrel
Selegiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Selegiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Selegiline {u} may lead to a major life threatening interaction when taken with {v} Fenfluramine
Selegiline (Compound) resembles Phenelzine (Compound)
Selegiline (Compound) resembles Benzyl alcohol (Compound)
Selegiline (Compound) binds MAOA (Gene)
Selegiline (Compound) palliates Alzheimer's disease (Disease)
Selegiline (Compound) is included by Monoamine Oxidase-B Inhibitors (Pharmacologic Class)
Selegiline (Compound) causes Thrombocytopenia (Side Effect)
Selegiline may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine
Selegiline may lead to a major life threatening interaction when taken with Fenfluramine